208 related articles for article (PubMed ID: 34632328)
21. A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters.
Bricker TL; Darling TL; Hassan AO; Harastani HH; Soung A; Jiang X; Dai YN; Zhao H; Adams LJ; Holtzman MJ; Bailey AL; Case JB; Fremont DH; Klein R; Diamond MS; Boon ACM
bioRxiv; 2020 Dec; ():. PubMed ID: 33299991
[TBL] [Abstract][Full Text] [Related]
22. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate.
Sun W; Leist SR; McCroskery S; Liu Y; Slamanig S; Oliva J; Amanat F; Schäfer A; Dinnon KH; García-Sastre A; Krammer F; Baric RS; Palese P
EBioMedicine; 2020 Dec; 62():103132. PubMed ID: 33232870
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
24. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
Park SI; Park S; Lee K; Kwak HW; Kim YK; Park HJ; Bang YJ; Kim JY; Kim D; Seo KW; Lee SJ; Kim H; Kim Y; Kim DH; Park HJ; Jung SY; Ga E; Hwang J; Na W; Hong SH; Lee SM; Nam JH
Vaccine; 2024 Jan; 42(2):69-74. PubMed ID: 38097457
[TBL] [Abstract][Full Text] [Related]
25. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
Front Immunol; 2021; 12():772240. PubMed ID: 34858430
[TBL] [Abstract][Full Text] [Related]
26. A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.
Malherbe DC; Kurup D; Wirblich C; Ronk AJ; Mire C; Kuzmina N; Shaik N; Periasamy S; Hyde MA; Williams JM; Shi PY; Schnell MJ; Bukreyev A
NPJ Vaccines; 2021 Jul; 6(1):91. PubMed ID: 34294728
[TBL] [Abstract][Full Text] [Related]
27. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.
Liu X; Park HS; Matsuoka Y; Santos C; Yang L; Luongo C; Moore IN; Johnson RF; Garza NL; Zhang P; Lusso P; Best SM; Buchholz UJ; Le Nouën C
bioRxiv; 2022 Dec; ():. PubMed ID: 36561185
[TBL] [Abstract][Full Text] [Related]
28. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters.
de Moor WRJ; Williamson AL; Schäfer G; Douglass N; Gers S; Sutherland AD; Blumenthal MJ; Margolin E; Shaw ML; Preiser W; Chapman R
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515096
[TBL] [Abstract][Full Text] [Related]
29. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine.
Sun W; McCroskery S; Liu WC; Leist SR; Liu Y; Albrecht RA; Slamanig S; Oliva J; Amanat F; Schäfer A; Dinnon KH; Innis BL; García-Sastre A; Krammer F; Baric RS; Palese P
Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33348607
[TBL] [Abstract][Full Text] [Related]
30. Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures.
Fulber JPC; Farnós O; Kiesslich S; Yang Z; Dash S; Susta L; Wootton SK; Kamen AA
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835266
[TBL] [Abstract][Full Text] [Related]
31. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.
Sun W; Liu Y; Amanat F; González-Domínguez I; McCroskery S; Slamanig S; Coughlan L; Rosado V; Lemus N; Jangra S; Rathnasinghe R; Schotsaert M; Martinez JL; Sano K; Mena I; Innis BL; Wirachwong P; Thai DH; Oliveira RDN; Scharf R; Hjorth R; Raghunandan R; Krammer F; García-Sastre A; Palese P
Nat Commun; 2021 Oct; 12(1):6197. PubMed ID: 34707161
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
Sunagar R; Prasad SD; Ella R; Vadrevu KM
Front Immunol; 2022; 13():1063679. PubMed ID: 36569867
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
Banihashemi SR; Es-Haghi A; Fallah Mehrabadi MH; Nofeli M; Mokarram AR; Ranjbar A; Salman M; Hajimoradi M; Razaz SH; Taghdiri M; Bagheri M; Dadar M; Hassan ZM; Eslampanah M; Salehi Najafabadi Z; Lotfi M; Khorasani A; Rahmani F
Front Immunol; 2022; 13():836745. PubMed ID: 35693788
[TBL] [Abstract][Full Text] [Related]
34. Absence of Vaccine-enhanced Disease With Unexpected Positive Protection Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model.
Li C; Chen YX; Liu FF; Lee AC; Zhao Y; Ye ZH; Cai JP; Chu H; Zhang RQ; Chan KH; Chiu KH; Lung DC; Sridhar S; Hung IF; To KK; Zhang AJ; Chan JF; Yuen KY
Clin Infect Dis; 2021 Aug; 73(3):e719-e734. PubMed ID: 33515458
[TBL] [Abstract][Full Text] [Related]
35. Live recombinant Newcastle disease virus vectored vaccine expressing the haemagglutinin of H9N2 avian influenza virus suppresses viral replication in chickens.
Lee J; Cho AY; Kim DH; Lee JB; Park SY; Choi IS; Lee SW; Song CS
Avian Pathol; 2023 Apr; 52(2):100-107. PubMed ID: 36377478
[TBL] [Abstract][Full Text] [Related]
36. Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection.
Wang S; Xu L; Mu T; Qin M; Zhao P; Xie L; Du L; Wu Y; Legrand N; Mouchain K; Fichet G; Liu Y; Yin W; Zhao J; Ji M; Gong B; Klein M; Wu K
Front Cell Infect Microbiol; 2022; 12():979641. PubMed ID: 36405962
[TBL] [Abstract][Full Text] [Related]
37. Intranasal administration of unadjuvanted SARS-CoV-2 spike antigen boosts antigen-specific immune responses induced by parenteral protein subunit vaccine prime in mice and hamsters.
Agbayani G; Akache B; Renner TM; Tran A; Stuible M; Dudani R; Harrison BA; Duque D; Bavananthasivam J; Deschatelets L; Hemraz UD; Régnier S; Durocher Y; McCluskie MJ
Eur J Immunol; 2024 Jun; 54(6):e2350620. PubMed ID: 38561974
[TBL] [Abstract][Full Text] [Related]
38. Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model.
Dhakal S; Ruiz-Bedoya CA; Zhou R; Creisher PS; Villano JS; Littlefield K; Ruelas Castillo J; Marinho P; Jedlicka AE; Ordonez AA; Bahr M; Majewska N; Betenbaugh MJ; Flavahan K; Mueller ARL; Looney MM; Quijada D; Mota F; Beck SE; Brockhurst J; Braxton AM; Castell N; Stover M; D'Alessio FR; Metcalf Pate KA; Karakousis PC; Mankowski JL; Pekosz A; Jain SK; Klein SL;
mBio; 2021 Aug; 12(4):e0097421. PubMed ID: 34253053
[TBL] [Abstract][Full Text] [Related]
39. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
40. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters.
Abdelnabi R; Pérez P; Astorgano D; Albericio G; Kerstens W; Thibaut HJ; Coelmont L; Weynand B; Labiod N; Delgado R; Montenegro D; Puentes E; Rodríguez E; Neyts J; Dallmeier K; Esteban M; García-Arriaza J
Front Immunol; 2023; 14():1163159. PubMed ID: 37920464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
